Monoclonal Antibodies Strongly Recommended in Long-term Care Facilities for COVID-19 Treatment and Post-Exposure Prophylaxis

The monoclonal antibody product REGEN-COV (casirivimab and imdevimab) is authorized by the U.S. Food and Drug Administration under Emergency Use Authorization (EUA) for treatment of mild to moderate COVID-19 infections and post-exposure prophylaxis after exposure for those at high risk for developing severe disease and/or hospitalization. See EUA for full prescribing information, treatment-covid19-eua-fact-sheet-for-hcp.pdf (regeneron.com).

I. WORK WITH YOUR MEDICAL DIRECTOR TO DETERMINE IF/WHEN YOU NEED TO INITIATE REGEN-COV THERAPY IN YOUR FACILITY TO PREVENT HOSPITALIZATIONS AND DEATHS

TREATMENT

COVID-19 positive residents at high risk (older age, obesity, pregnancy, chronic kidney disease, diabetes, immunosuppression, cardiovascular disease, chronic lung disease, sickle cell disease, neurodevelopment disorder, medical-related technological dependence, or other conditions or factors such as race or ethnicity that may place an individual at high risk for disease progression)

- REGEN-COV is not authorized for use in patients who require oxygen therapy due to COVID-19 or require an increase in baseline oxygen flow rate due to COVID-19
- Use this clinical decision-making tool to help determine in a timely manner individuals who should receive treatment with monoclonal antibodies https://apps.msdh.ms.gov/redcap/surveys/?s=RHK3C3HEJ8897TPL

POST-EXPOSURE PROPHYLAXIS

Residents who are not fully vaccinated or not expected to mount an adequate immune response to vaccination and have been exposed or are at high risk of exposure because of COVID-19 infection in other individuals in the same institutional setting

II. WORK WITH YOUR LONG-TERM CARE PHARMACY TO OBTAIN REGEN-COV

- Have a plan in place now for how you will obtain monoclonal antibodies before the need arises
- Partner with your long-term care pharmacy to obtain REGEN-COV product
- Order product from AmerisourceBergen: C19 Therapies Direct Order Request (smartsheet.com)

*REGEN-COV can now be given subcutaneously (FDA Authorizes Lower IV and SQ Dose of REGEN-COV).

If you have any questions about monoclonal antibodies for COVID-19 treatment and post-exposure prophylaxis, please email monoclonals@msdh.ms.gov